Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Beijing Immunochina Medical Science & Technology Co., Ltd.
Modality
Cell therapy
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05287165CT.gov Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Digestive System Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| im96 car-t cells (this asset) | Beijing Immunochina Medical Science & Technology Co., Ltd. | Early P1 | C · 39 |
| Capecitabine | China Medical University, China | P3 | BB |
| Sorafenib | Sichuan Cancer Hospital and Research Institute | P3 | BB |
| Irinotecan | Pfizer | P3 | BB |
| Fluorouracilum | Janssen Research & Development, LLC | P3 | B |
| Cis-Diamminedichloroplatinum Ii | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P1/2 | B |
| Catequentinib | Zhejiang University | P2 | B |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | Federico II University | P2 | B |
| Acetylcysteine | German Cancer Research Center | P2 | B |
+41 more in the Digestive System Neoplasm cohort
Other indications for im96 car-t cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P1 | CCC · 50 |
| Pancreatic Adenocarcinoma | — | Early P1 | C · 38 |
| Cancer | — | Early P1 | C · 33 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. im96 car-t cells in Digestive System Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/im96-car-t-cells-digestive-system-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →